Plain-English fact sheet
Retatrutide
Also known as LY3437943
Retatrutide is an investigational peptide-based medicine with Phase 3 data emerging from company-reported trials; it is not FDA approved.
Quick answer
Retatrutide activates GIP, GLP-1, and glucagon receptors and is being studied in Phase 3 programs. It is not an FDA-approved medicine.
By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.
What is Retatrutide?
Retatrutide is a manufactured peptide designed to activate three metabolic signaling receptors.
It remains a research drug. Registered trials are testing both benefits and risks in defined populations.
Why are people interested in it?
Early human studies reported substantial average weight changes, which generated strong public interest.
Phase 3 trials are intended to test whether those results hold up in larger, more diverse groups and to characterize safety more completely.
Current regulatory status
Retatrutide is not FDA approved. Some Phase 3 studies have reported company-provided top-line results, while other Phase 3, head-to-head, and outcomes studies remain ongoing or active in registries.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
FDA approval path
Late-stage clinical development
Retatrutide has Phase 3 trial records and company-reported top-line results, while other Phase 3 and outcomes studies remain in the registry. It is not FDA approved.
Step 5 of 7
- DiscoveryBasic research
- PreclinicalLab and animal work
- Phase 1Initial human testing
- Phase 2Condition-focused trials
- Phase 3Confirmatory trials
- FDA reviewApplication review
- ApprovedLabel-specific use
What is it being studied for?
Investigational areas
- Body-weight reduction and maintenance
- Metabolic and cardiovascular outcomes
- Obesity-related conditions
Evidence snapshot
A published Phase 2 obesity trial and company-reported Phase 3 top-line results provide human evidence, but peer-reviewed Phase 3 publications, full regulatory review, and longer outcomes data remain pending.
Potential benefits being researched
- Earlier trials observed changes in body weight and metabolic measures.
- Company-reported Phase 3 top-line results describe substantial weight changes in defined trial populations, but those reports should not be treated as FDA approval or complete published evidence.
- Ongoing Phase 3 and outcomes trials are designed to provide more reliable estimates of benefits and harms over time.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Earlier trials reported gastrointestinal adverse effects, among other events.
- A research program may identify uncommon or longer-term risks only after larger and longer studies.
- Products marketed online as retatrutide are not an FDA-approved version of the investigational drug.
What we still do not know
- How company-reported Phase 3 top-line findings will look after full peer-reviewed publication and regulatory review
- The complete adverse-effect profile across larger populations
- Which indications, populations, or product presentations might eventually be reviewed by regulators
- Long-term cardiovascular and kidney outcomes
Related research updates
Plain-English takeaway
Retatrutide is promising research, not an approved treatment. Phase 3 results and regulatory review—not online availability or early headlines—will determine what claims are supported.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1clinical trialsClinicalTrials.gov: TRIUMPH-1 Phase 3 study
Registered Phase 3 obesity master trial with knee-osteoarthritis and obstructive-sleep-apnea substudies.
- 2company releaseLilly: TRIUMPH-1 top-line results
Company-provided Phase 3 top-line obesity results; not a peer-reviewed publication or FDA approval.
- 3clinical trialsClinicalTrials.gov: TRIUMPH-5 Phase 3 study
Registered Phase 3 comparison of retatrutide and tirzepatide in adults with obesity.
- 4clinical trialsClinicalTrials.gov: TRIUMPH-Outcomes
Registered cardiovascular and kidney outcomes trial.
- 5pubmedNEJM Phase 2 obesity trial indexed in PubMed
Peer-reviewed Phase 2 dose-finding obesity trial that preceded the Phase 3 program.